Biotechnology | Disease | FDA | Therapeutics
FDA approved orphan drug Elelyso to treat a form of Gaucher disease
On May 1, 2012, the U.S. Food and Drug Administration (FDA) approved new orphan drug Elelyso to treat…
Biotechnology | Diagnostics | Disease | FDA | Therapeutics
FDA approved Elelyso (taliglucerase alfa) for long-term enzyme replacement therapy to treat a form of Gaucher disease
In 2007, the U.S. Food and Drug Administration (FDA) approved Elelyso (taliglucerase alfa) for long-term enzyme replacement therapy…
Genzyme launched an IPO at $10 a share, raising $28.3 million
On Jun. 5, 1986, Genzyme launched an Initial Public Offering (IPO) at $10 a share, and raised $28.3…